United Therapeutics Corpo... (UTHR)
284.24
-0.49 (-0.17%)
At close: Apr 21, 2025, 3:59 PM
298.30
4.95%
After-hours: Apr 21, 2025, 04:31 PM EDT
United Therapeutics Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Jun 30, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adcirca Revenue | 7M | 5.7M | 6.4M | 6.8M | 7.3M | 7.5M | 7.3M | 10.4M | 10.7M | 10.4M | 9.8M | 8.1M | 14.6M | 23.6M | 9.6M | 21.6M | 13.8M | 19.4M | 12.5M | 27.8M | 30.3M | 29.1M | 58.4M | 41.7M | 74.6M | 109.8M | 97.6M | 93.1M | 99.8M | 120.6M | 80M | 112.7M | 96M | 90.9M | 72.6M | 91.58M | 73.8M | 68.08M | 45.37M | 73.55M | 51.25M | 55.32M | 41.36M | 52.05M | 47.38M | 43.73M | 33.82M | 38.18M | 31.8M | 30.22M | 22.33M | 22.65M | 16.84M |
| Adcirca Revenue Growth | +22.81% | -10.94% | -5.88% | -6.85% | -2.67% | +2.74% | -29.81% | -2.80% | +2.88% | +6.12% | +20.99% | -44.52% | -38.14% | +145.83% | -55.56% | +56.52% | -28.87% | +55.20% | -55.04% | -8.25% | +4.12% | -50.17% | +40.05% | -44.10% | -32.06% | +12.50% | +4.83% | -6.71% | -17.25% | +50.75% | -29.02% | +17.40% | +5.61% | +25.21% | -20.73% | +24.10% | +8.40% | +50.06% | -38.31% | +43.51% | -7.36% | +33.74% | -20.53% | +9.86% | +8.35% | +29.29% | -11.42% | +20.05% | +5.23% | +35.35% | -1.40% | +34.46% | n/a |
| Orenitram Revenue | 113.2M | 107.1M | 106.2M | 84.1M | 92M | 95.1M | 88.2M | 75.8M | 87.5M | 79M | 82.8M | 72.3M | 85.2M | 76.2M | 72.4M | 74M | 74.7M | 75.4M | 69M | 50.9M | 62M | 54M | 24.9M | 49.6M | 53.8M | 49.5M | 52.2M | 48M | 52.5M | 46M | 39.3M | 38.3M | 40.7M | 38M | 40.2M | 37.29M | 34.39M | 25.87M | 20.89M | 20.18M | 14.46M | 6.63M | 136.11M | 119.86M | 132.32M | 124.31M | 114.68M | 116.21M | 120.81M | 110.4M | 110.55M | 107.12M | 104.89M |
| Orenitram Revenue Growth | +5.70% | +0.85% | +26.28% | -8.59% | -3.26% | +7.82% | +16.36% | -13.37% | +10.76% | -4.59% | +14.52% | -15.14% | +11.81% | +5.25% | -2.16% | -0.94% | -0.93% | +9.28% | +35.56% | -17.90% | +14.81% | +116.87% | -49.80% | -7.81% | +8.69% | -5.17% | +8.75% | -8.57% | +14.13% | +17.05% | +2.61% | -5.90% | +7.11% | -5.47% | +7.81% | +8.43% | +32.93% | +23.86% | +3.52% | +39.52% | +118.03% | -95.13% | +13.55% | -9.41% | +6.44% | +8.40% | -1.32% | -3.81% | +9.43% | -0.13% | +3.20% | +2.12% | n/a |
| Product and Service, Other Revenue | 5.5M | 4.9M | 6.2M | 3.9M | 1.9M | 3.5M | 2.5M | 3.8M | 114M | 132M | 131.7M | 118.3M | 125.4M | 139.8M | 130.2M | 127.9M | 124.5M | 119M | 145.3M | 107.4M | 168.3M | 155.8M | 155.5M | 159.1M | 153.6M | 159.5M | 126.8M | 180.1M | 187.3M | 157.7M | 145.8M | 151.2M | 152.4M | 158.9M | 139.8M | 140.48M | 150.07M | 135.96M | 146.28M | 136.59M | 142.88M | 138.15M | 107.09M | 114.38M | 120.31M | 109.46M | 94.64M | 86.04M | 88.3M | 81.21M | 70.07M | 64.55M | 61.81M |
| Product and Service, Other Revenue Growth | +12.24% | -20.97% | +58.97% | +105.26% | -45.71% | +40.00% | -34.21% | -96.67% | -13.64% | +0.23% | +11.33% | -5.66% | -10.30% | +7.37% | +1.80% | +2.73% | +4.62% | -18.10% | +35.29% | -36.19% | +8.02% | +0.19% | -2.26% | +3.58% | -3.70% | +25.79% | -29.59% | -3.84% | +18.77% | +8.16% | -3.57% | -0.79% | -4.09% | +13.66% | -0.49% | -6.39% | +10.38% | -7.06% | +7.09% | -4.40% | +3.42% | +29.01% | -6.38% | -4.92% | +9.91% | +15.65% | +10.01% | -2.57% | +8.73% | +15.90% | +8.55% | +4.43% | n/a |
| Remodulin Revenue | 128.3M | 147.3M | 128M | 115.1M | 131.1M | 127.2M | 121.4M | 122.5M | 257.7M | 201M | 172M | 166.5M | 164.2M | 153.8M | 123M | 29.7M | 129.5M | 119.2M | 102.9M | 33.6M | 110.8M | 109.6M | 103.8M | 24.1M | 107.8M | 105.9M | 94.6M | 24.9M | 88.9M | 104.2M | 87.4M | 93.6M | 101.8M | 107M | 102.2M | 119.13M | 121.72M | 115.84M | 113.38M | 115.07M | 119.69M | 121.23M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Remodulin Revenue Growth | -12.90% | +15.08% | +11.21% | -12.20% | +3.07% | +4.78% | -0.90% | -52.46% | +28.21% | +16.86% | +3.30% | +1.40% | +6.76% | +25.04% | +314.14% | -77.07% | +8.64% | +15.84% | +206.25% | -69.68% | +1.09% | +5.59% | +330.71% | -77.64% | +1.79% | +11.95% | +279.92% | -71.99% | -14.68% | +19.22% | -6.62% | -8.06% | -4.86% | +4.70% | -14.21% | -2.13% | +5.07% | +2.17% | -1.47% | -3.86% | -1.27% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Tyvaso Revenue | 433.8M | 398.2M | 372.5M | 676.4M | 51.3M | 318.9M | 238.4M | 242.3M | 46.1M | 44.5M | 55.6M | 50M | 55.3M | 53.1M | 43.9M | n/a | 37.6M | 29M | 26.6M | n/a | 30.1M | 25.1M | 20M | n/a | 22.9M | 19.8M | 18M | n/a | 17M | 16.1M | 18M | 13.2M | 17.3M | 17.8M | 14.2M | 15.71M | 4.73M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Tyvaso Revenue Growth | +8.94% | +6.90% | -44.93% | +1218.52% | -83.91% | +33.77% | -1.61% | +425.60% | +3.60% | -19.96% | +11.20% | -9.58% | +4.14% | +20.96% | n/a | n/a | +29.66% | +9.02% | n/a | n/a | +19.92% | +25.50% | n/a | n/a | +15.66% | +10.00% | n/a | n/a | +5.59% | -10.56% | +36.36% | -23.70% | -2.81% | +25.35% | -9.63% | +232.29% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Unituxin Revenue | 61.1M | 51.7M | 58.4M | 54.2M | n/a | 44.3M | 49.1M | 36.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Unituxin Revenue Growth | +18.18% | -11.47% | +7.75% | n/a | n/a | -9.78% | +33.79% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 125.3M | 122.2M | 121.3M | 1.41B | 1.03B | 846.61M | 676.97M |
| Non-Us Revenue Growth | +2.54% | +0.74% | -91.41% | +36.77% | +21.95% | +25.06% | n/a |
| United States Revenue | 2.2B | 1.81B | 1.56B | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +21.39% | +15.98% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 219.2M | 177.6M | 144.4M | 132.2M | 127.6M | 130M | 87.3M | 166.1M | 98.4M | 141.5M | 79M | 127.9M | 109.1M | 112.8M | 117.2M | 158.7M | 66.3M | 105.9M | 93M | 105.2M | 99.4M | 39.6M | 92M | 79.2M | 110.1M | 83.1M | -6.6M | 159.1M | 47.2M | 67.4M | 56.4M | 139.5M | 100.1M | 72.2M | 5M | 148.56M | -17.28M | 109.99M | 211.34M |
| Selling, General, and Administrative Revenue Growth | +23.42% | +22.99% | +9.23% | +3.61% | -1.85% | +48.91% | -47.44% | +68.80% | -30.46% | +79.11% | -38.23% | +17.23% | -3.28% | -3.75% | -26.15% | +139.37% | -37.39% | +13.87% | -11.60% | +5.84% | +151.01% | -56.96% | +16.16% | -28.07% | +32.49% | -1359.09% | -104.15% | +237.08% | -29.97% | +19.50% | -59.57% | +39.36% | +38.64% | +1344.00% | -96.63% | -959.93% | -115.71% | -47.96% | n/a |
| Research and Development Revenue | 103.5M | 139.6M | 104.1M | 151.4M | 84.7M | 89M | 82.9M | 93.9M | 66.1M | 93.9M | 69M | 82.9M | 79.2M | 74.3M | 303.7M | 126.1M | 68.7M | 89.7M | 73.2M | 113.6M | 85.7M | 85.9M | 897.4M | 138.8M | 101.1M | 82.3M | 35.7M | 113.6M | 55M | 59.8M | 36.2M | 66.9M | 45.9M | 35.2M | -400K | 75.95M | 9.53M | 49.41M | 110.21M |
| Research and Development Revenue Growth | -25.86% | +34.10% | -31.24% | +78.75% | -4.83% | +7.36% | -11.71% | +42.06% | -29.61% | +36.09% | -16.77% | +4.67% | +6.59% | -75.54% | +140.84% | +83.55% | -23.41% | +22.54% | -35.56% | +32.56% | -0.23% | -90.43% | +546.54% | +37.29% | +22.84% | +130.53% | -68.57% | +106.55% | -8.03% | +65.19% | -45.89% | +45.75% | +30.40% | -8900.00% | -100.53% | +697.19% | -80.72% | -55.17% | n/a |
| Sales and Marketing Revenue | 20.7M | 25.4M | 23.2M | 24.1M | 20.7M | 20.1M | 16.9M | 23M | 17.2M | 16.1M | 14.5M | 16.4M | 17.2M | 17.1M | 13.7M | 16.8M | 12.4M | 12.7M | 13M | 18.6M | 14.8M | 13.7M | 13.6M | -28.9M | n/a | 15.6M | 13.3M | 17.6M | 15.8M | 15.5M | 15.4M | -67.1M | 20.1M | 24.7M | 22.3M | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | -18.50% | +9.48% | -3.73% | +16.43% | +2.99% | +18.93% | -26.52% | +33.72% | +6.83% | +11.03% | -11.59% | -4.65% | +0.58% | +24.82% | -18.45% | +35.48% | -2.36% | -2.31% | -30.11% | +25.68% | +8.03% | +0.74% | -147.06% | n/a | -100.00% | +17.29% | -24.43% | +11.39% | +1.94% | +0.65% | -122.95% | -433.83% | -18.62% | +10.76% | n/a | n/a | n/a | n/a | n/a |